In its latest trading update, ASX-listed technology company Chrysos Corporation has reported that it achieved a new fleet record in March, processing over one-million samples in a single month, underscoring the growing productivity and utilisation of the company’s deployed PhotonAssay network.

This was followed in April with a second consecutive month of processing more than one-million samples.

The company says record sample volumes underpin higher utilisation and accelerate additional assay charges (AAC), a key revenue and profitability driver.

Chrysos has now signed 19 new PhotonAssay lease agreements, including five new contracts since the company’s last update, reflecting the company’s broadening international relationship with both miners and laboratories.

This includes a further two agreements secured with ASX-listed ALS, with 16 units now within that growing partnership. Four of the recent agreements with ALS are related to entering new regions for Chrysos, where ALS has established laboratory operations.

Additionally, a second lease agreement with global testing, inspection and certification company Bureau Veritas, for deployment into Australia, expands Chrysos’ relationship with another of the world’s largest laboratories shortly after the initial agreement for deployment in South America.

Moreover, Chrysos continues to grow a direct-to-mine presence, firstly with an expansion of the relationship with TSX-listed Allied Gold, which has now secured a subsequent lease agreement for their Kurmuk mine site, in Ethiopia, as well as an additional miner-contracted unit for deployment later in the calendar year.

Meanwhile, Chrysos says a further three units have completed factory acceptance testing, adding that eight PhotonAssay units are now either being shipped to, or are stored near, their deployment locations as the company looks to accelerate deployments into its 2027 financial year.

The company says it is on track to achieve its 2026 financial year guidance.

Revenue is tracking at the upper end of the $80-million to $90-million guidance range, while earnings before interest, taxes, depreciation and amortisation are tracking at the upper end of the $20-million to $27-million guidance range.

Further, Chrysos is currently deploying one PhotonAssay unit in Chile and says it is well positioned for an accelerated deployment cadence in the 2027 financial year.

Additionally, deployment has been completed at Grand Falls-Windsor, Canada, for international laboratory business MSALABS – a subsidiary of London-listed Capital – taking the fleet to 44 deployed units.

Chrysos’ previously announced refinancing to a total level of $200-million remains on track to be completed before June 30.